Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 20'th Aug 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Alkermes (ALKS) is a Strong Value Stock
10:40am, Monday, 19'th Aug 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term
10:51am, Friday, 16'th Aug 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
10:45am, Thursday, 01'st Aug 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Alkermes (ALKS) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 30'th Jul 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
11:46am, Thursday, 25'th Jul 2024
Alkermes (ALKS) reports mixed second-quarter 2024 results. Earnings and revenues decline year over year.
Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say
10:35am, Wednesday, 24'th Jul 2024
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Alkermes (ALKS) Lags Q2 Earnings Estimates
09:15am, Wednesday, 24'th Jul 2024
Alkermes (ALKS) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.55 per share a year ago.
Alkermes plc Reports Second Quarter 2024 Financial Results
07:00am, Wednesday, 24'th Jul 2024
— Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from Continuing Operations
Alkermes to Report Second Quarter Financial Results on July 24, 2024
04:00pm, Wednesday, 17'th Jul 2024
DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q2 Release
11:07am, Wednesday, 17'th Jul 2024
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested — �
Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?
12:36pm, Friday, 31'st May 2024
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes to Participate in Two Upcoming Investor Conferences
04:00pm, Wednesday, 29'th May 2024
DUBLIN , May 29, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Jefferies Health
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
07:00am, Tuesday, 28'th May 2024
– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations – – Findi
